Last reviewed · How we verify

MOVANTIK™ (naloxegol) — Competitive Intelligence Brief

MOVANTIK™ (naloxegol) (MOVANTIK™ (naloxegol)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peripheral opioid receptor antagonist. Area: Gastroenterology / Pain Management.

marketed Peripheral opioid receptor antagonist Mu-opioid receptor (peripheral) Gastroenterology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

MOVANTIK™ (naloxegol) (MOVANTIK™ (naloxegol)) — Massachusetts General Hospital. Naloxegol is a peripheral mu-opioid receptor antagonist that blocks opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MOVANTIK™ (naloxegol) TARGET MOVANTIK™ (naloxegol) Massachusetts General Hospital marketed Peripheral opioid receptor antagonist Mu-opioid receptor (peripheral)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Peripheral opioid receptor antagonist class)

  1. Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MOVANTIK™ (naloxegol) — Competitive Intelligence Brief. https://druglandscape.com/ci/movantik-naloxegol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: